These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8398303)

  • 1. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma.
    Coates A; Thomson D; McLeod GR; Hersey P; Gill PG; Olver IN; Kefford R; Lowenthal RM; Beadle G; Walpole E
    Eur J Cancer; 1993; 29A(12):1731-4. PubMed ID: 8398303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group.
    Coates A; Gebski V; Signorini D; Murray P; McNeil D; Byrne M; Forbes JF
    J Clin Oncol; 1992 Dec; 10(12):1833-8. PubMed ID: 1453197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced malignant melanoma with recombinant interferon alfa-2a in combination with DTIC: long-term follow-up of two phase II studies.
    Hersey P; McLeod GR; Thomson DB
    Br J Haematol; 1991 Oct; 79 Suppl 1():60-6. PubMed ID: 1931712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial.
    Thomson DB; Adena M; McLeod GR; Hersey P; Gill PG; Coates AS; Olver IN; Kefford RF; Lowenthal RM; Beadle GF
    Melanoma Res; 1993 Apr; 3(2):133-8. PubMed ID: 8518552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer.
    Lee CK; Stockler MR; Coates AS; Gebski V; Lord SJ; Simes RJ;
    Br J Cancer; 2010 Apr; 102(9):1341-7. PubMed ID: 20389302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the receiving end--III. Measurement of quality of life during cancer chemotherapy.
    Coates A; Glasziou P; McNeil D
    Ann Oncol; 1990; 1(3):213-7. PubMed ID: 2261367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy.
    Coates A; Porzsolt F; Osoba D
    Eur J Cancer; 1997 Jun; 33(7):1025-30. PubMed ID: 9376182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of quality-of-life scores: preliminary results of an analysis of patients with breast cancer.
    Shimozuma K; Sonoo H; Ichihara K; Tanaka K
    Surg Today; 2000; 30(3):255-61. PubMed ID: 10752779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.
    Falkson CI; Falkson G; Falkson HC
    J Clin Oncol; 1991 Aug; 9(8):1403-8. PubMed ID: 2072144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality-of-life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group.
    Coates AS; Hürny C; Peterson HF; Bernhard J; Castiglione-Gertsch M; Gelber RD; Goldhirsch A
    J Clin Oncol; 2000 Nov; 18(22):3768-74. PubMed ID: 11078489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial.
    Semiglazov VF; Stepula VV; Dudov A; Schnitker J; Mengs U
    Anticancer Res; 2006; 26(2B):1519-29. PubMed ID: 16619567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
    Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
    Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
    Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.
    Falkson CI; Ibrahim J; Kirkwood JM; Coates AS; Atkins MB; Blum RH
    J Clin Oncol; 1998 May; 16(5):1743-51. PubMed ID: 9586887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study.
    Hauschild A; Dummer R; Ugurel S; Kaehler KC; Egberts F; Fink W; Both-Skalsky J; Laetsch B; Schadendorf D
    Cancer; 2008 Sep; 113(6):1404-11. PubMed ID: 18615619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of metastatic melanoma with dacarbazine recombinant interferon alfa 2A combination: results of multicentric study].
    Avril MF; Beerblock K; Dreno B; Delaunay M; Bonerandi JJ; Guillaume JC; Souteyrand P; Kalis B; Chevrant-Breton J; Verret J
    Bull Cancer; 1990; 77(12):1183-91. PubMed ID: 2081278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer.
    Kramer JA; Curran D; Piccart M; de Haes JC; Bruning P; Klijn J; Van Hoorebeeck I; Paridaens R
    Eur J Cancer; 2000 Aug; 36(12):1498-506. PubMed ID: 10930797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma.
    Mulder NH; Willemse PH; Schraffordt Koops H; de Vries EG; Sleijfer DT
    Br J Cancer; 1990 Dec; 62(6):1006-7. PubMed ID: 2257203
    [No Abstract]   [Full Text] [Related]  

  • 20. Chemoimmunotherapy of metastatic malignant melanoma. The Salpétrière Hospital (SOMPS) experience.
    Khayat D; Antoine E; Rixe O; Tourani JM; Vuillemin E; Borel C; Benhammouda A; Thill L; Franks C; Auclerc G
    Eur J Cancer; 1993; 29A Suppl 5():S2-5. PubMed ID: 8260262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.